
BiotechTV - News Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases
May 15, 2025
Chapters
Transcript
Episode notes
